33008436|t|Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease.
33008436|a|BACKGROUND: Lysophosphatidic acids (LPAs) are bioactive signaling phospholipids that have been implicated in Alzheimer's disease (AD). It is largely unknown whether LPAs are associated with AD pathology and progression from mild cognitive impairment (MCI) to AD. METHODS: The current study was performed on cerebrospinal fluid (CSF) and plasma samples of 182 MCI patients from two independent cohorts. We profiled LPA-derived metabolites using liquid chromatography-mass spectrometry. We evaluated the association of LPAs with CSF biomarkers of AD, Abeta-42, p-tau, and total tau levels overall and stratified by APOE genotype and with MCI to AD progression. RESULTS: Five LPAs (C16:0, C16:1, C22:4, C22:6, and isomer-LPA C22:5) showed significant positive association with CSF biomarkers of AD, Abeta-42, p-tau, and total tau, while LPA C14:0 and C20:1 associated only with Abeta-42 and alkyl-LPA C18:1, and LPA C20:1 associated with tau pathology biomarkers. Association of cyclic-LPA C16:0 and two LPAs (C20:4, C22:4) with Abeta-42 levels was found only in APOE epsilon4 carriers. Furthermore, LPA C16:0 and C16:1 also showed association with MCI to AD dementia progression, but results did not replicate in an independent cohort. CONCLUSIONS: Our findings provide evidence that LPAs may contribute to early AD pathogenesis. Future studies are needed to determine whether LPAs play a role in upstream of AD pathology or are downstream markers of neurodegeneration.
33008436	15	37	lysophosphatidic acids	Chemical	MESH:D008246
33008436	93	112	Alzheimer's disease	Disease	MESH:D000544
33008436	126	148	Lysophosphatidic acids	Chemical	MESH:D008246
33008436	150	154	LPAs	Chemical	MESH:D008246
33008436	180	193	phospholipids	Chemical	MESH:D010743
33008436	223	242	Alzheimer's disease	Disease	MESH:D000544
33008436	244	246	AD	Disease	MESH:D000544
33008436	279	283	LPAs	Chemical	MESH:D008246
33008436	304	306	AD	Disease	MESH:D000544
33008436	338	363	mild cognitive impairment	Disease	MESH:D060825
33008436	365	368	MCI	Disease	MESH:D060825
33008436	373	375	AD	Disease	MESH:D000544
33008436	473	476	MCI	Disease	MESH:D060825
33008436	477	485	patients	Species	9606
33008436	528	531	LPA	Gene	4018
33008436	631	635	LPAs	Chemical	MESH:D008246
33008436	659	661	AD	Disease	MESH:D000544
33008436	663	671	Abeta-42	Gene	351
33008436	690	693	tau	Gene	4137
33008436	727	731	APOE	Gene	348
33008436	750	753	MCI	Disease	MESH:D060825
33008436	757	759	AD	Disease	MESH:D000544
33008436	787	791	LPAs	Chemical	MESH:D008246
33008436	793	798	C16:0	Chemical	-
33008436	800	805	C16:1	Chemical	-
33008436	807	812	C22:4	Chemical	-
33008436	832	835	LPA	Gene	4018
33008436	906	908	AD	Disease	MESH:D000544
33008436	910	918	Abeta-42	Gene	351
33008436	937	940	tau	Gene	4137
33008436	948	951	LPA	Gene	4018
33008436	989	997	Abeta-42	Gene	351
33008436	1008	1011	LPA	Gene	4018
33008436	1023	1026	LPA	Gene	4018
33008436	1049	1052	tau	Gene	4137
33008436	1097	1100	LPA	Gene	4018
33008436	1101	1106	C16:0	Chemical	-
33008436	1115	1119	LPAs	Chemical	MESH:D008246
33008436	1128	1133	C22:4	Chemical	-
33008436	1140	1148	Abeta-42	Gene	351
33008436	1174	1178	APOE	Gene	348
33008436	1211	1214	LPA	Gene	4018
33008436	1215	1220	C16:0	Chemical	-
33008436	1225	1230	C16:1	Chemical	-
33008436	1260	1263	MCI	Disease	MESH:D060825
33008436	1267	1278	AD dementia	Disease	MESH:D000544
33008436	1396	1400	LPAs	Chemical	MESH:D008246
33008436	1425	1427	AD	Disease	MESH:D000544
33008436	1489	1493	LPAs	Chemical	MESH:D008246
33008436	1521	1523	AD	Disease	MESH:D000544
33008436	1563	1580	neurodegeneration	Disease	MESH:D019636
33008436	Association	4018	4137
33008436	Association	MESH:D000544	4018
33008436	Association	MESH:D008246	MESH:D000544
33008436	Association	MESH:D008246	MESH:D019636
33008436	Association	MESH:D008246	4137
33008436	Association	351	4018
33008436	Association	MESH:D008246	351

